Sutro Biopharma (STRO) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sutro Biopharma (STRO) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 74.5% versus a loss of 18.3%. Over five years, STRO leads with a -92.3% price change compared with -98.2% for XFOR. X4 Pharmaceuticals is the larger company by market cap ($276.6 million vs $254.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STRO | XFOR |
|---|---|---|
| Share price | $15.32 | $2.79 |
| Market cap | $254.02M | $276.62M |
| 1-day change | +4.50% | -0.71% |
| YTD return | +26.71% | -29.75% |
| 1-year return | +74.52% | -18.31% |
| 5-year return | -92.28% | -98.21% |
| P/E ratio (TTM) | — | 139.50 |
| EPS (TTM) | $-17.28 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.85 | $4.83 |
| 52-week low | $7.15 | $2.70 |
| Distance from 52-week high | -65.06% | -42.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +208.29% | +315.77% |
| Average volume | 286.74K | 843.50K |
| Shares outstanding | 16.58M | 99.15M |
| Employees | 128 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed XFOR by 92.8 percentage points over the past year.
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 128 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
STRO vs XFOR FAQ
Which is bigger, Sutro Biopharma or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $276.62M compared with $254.02M for Sutro Biopharma (STRO).
Which stock has performed better over the past year, STRO or XFOR?
STRO returned +74.52% over the past 12 months, compared with -18.31% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are Sutro Biopharma and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.